ADVANCED MEDICINE PARTNERS

Serial Number 98360100
Registration 7863281
700

Registration Progress

Application Filed
Jan 16, 2024
Under Examination
Approved for Publication
May 27, 2025
Published for Opposition
May 27, 2025
Registered
Jul 15, 2025

Trademark Image

ADVANCED MEDICINE PARTNERS

Basic Information

Serial Number
98360100
Registration Number
7863281
Filing Date
January 16, 2024
Registration Date
July 15, 2025
Published for Opposition
May 27, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jul 15, 2025
Registration
Registered
Classes
040 042

Rights Holder

JAGUAR GENE THERAPY, LLC

16
Address
TWO CONWAY PARK, SUITE 300
LAKE FOREST, IL 60045

Ownership History

Advanced Medicine Partners, LLC

Original Applicant
16
Lake Forest, IL

JAGUAR GENE THERAPY, LLC

New Owner Before Publication #1
16
LAKE FOREST, IL

JAGUAR GENE THERAPY, LLC

Owner at Publication
16
LAKE FOREST, IL

JAGUAR GENE THERAPY, LLC

Original Registrant
16
LAKE FOREST, IL

Legal Representation

Attorney
J. Dickson Phillips III

USPTO Deadlines

Next Deadline
2004 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250715)
Due Date
July 15, 2031
Grace Period Ends
January 15, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

24 events
Date Code Type Description Documents
Jul 15, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jul 15, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 27, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 27, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 21, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 28, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 2, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 2, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 2, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 2, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 2, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 2, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 20, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 20, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 20, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 5, 2025 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Nov 15, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Nov 15, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Aug 20, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 20, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 20, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 12, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
May 13, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 16, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 040
Biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organism in the manufacturing process; custom manufacture for others of products relating to biotechnology, namely, recombinant proteins for use in the biotechnology industries; custom manufacture for others of cell therapy products; custom manufacture for others of gene therapy products; custom manufacture of pharmaceuticals in accordance with specific standards GMP regulations
First Use Anywhere: Oct 2, 2023
First Use in Commerce: Oct 2, 2023
Class 042
Contract development and manufacturing organization (CDMO) services, namely, pharmaceutical drug development services; consulting and advisory services in the field of analytical development and quality control testing of pharmaceutical, gene therapy, and cell therapy products; consulting and advisory services in the field of manufacturing process development for pharmaceutical, gene therapy and cell therapy products; consulting in the field of chemistry manufacturing and controls (CMC) activities; testing of pharmaceutical, gene therapy, and cell therapy products and materials; quality control testing of pharmaceutical products and materials, namely, biopharmaceutical products and materials in accordance with specifications or requirements of regulatory standards applicable in target countries; testing and validation services of biopharmaceutical products to assure compliance with global regulatory requirements, specifications, and industry standards for pharmaceutical, cell therapy and gene therapy methods of development; technical consulting for regulatory compliance in the field of chemistry manufacturing and controls (CMC)
First Use Anywhere: Oct 2, 2023
First Use in Commerce: Oct 2, 2023

Classification

International Classes
040 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"MEDICINE"